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High-dose Atorvastatin After Stroke or Transient Ischemic Attack
Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
N Engl J Med 2006;355:549-59.
Conclusion: Patients without known coronary heart disease who have
had a recent stroke or transient ischemic attack (TIA) have a reduction in
overall incidence of stroke and cardiovascular events with 80 mg of atorva-
statin per day.
Summary: It is known statins reduce the risk of stroke in patients at
increased risk for cardiovascular disease. The authors sought to determine
whether there was a reduction in stroke after recent stroke or TIA with the
use of statin medication. This was a randomized double-blind study. Eligible
patients had a stroke or TIA within in 1 to 6 months before study entry.
Low-density lipoprotein (LDL) cholesterol levels were required to be be-
tween 100 to 190 mg/dL. The patients had no known coronary heart
disease. Randomization was to 80mg of atorvastatin per day or placebo. The
primary end point was a first nonfatal or fatal stroke.
During the course or the trial, the mean LDL cholesterol level in
patients receiving atorvastatin was 73mg/dL, and patients receiving placebo
had a mean LDL cholesterol level of 129mg/dL. Median follow-up was 4.9
years. During follow-up, 265 patients (11.2%) receiving atorvastatin and
313 patients (13.1%) receiving placebo had a nonfatal or fatal stroke. This
was an absolute risk reduction of 2.2% (adjusted hazard ratio [HR], 0.84;
95% confidence interval [CI], 0.71 to 0.99; P  .03). The placebo group
had 274 ischemic strokes and 33 hemorrhagic strokes. The atorvastatin
group had 55 hemorrhagic strokes and 218 ischemic strokes. In the patients
receiving atorvastatin, the 5-year absolute risk reduction in the risk of major
cardiovascular events was 3.5% (HR, 0.8; 95% CI, 0.69 to 0.92; P  .002).
Overall mortality was similar between the two groups (P  .98). Rates of
serious adverse events were also similar between the two groups. Elevated
liver enzyme values were more common in patients taking the statin medi-
cation.
Comment: Medications active in reducing cardiovascular end points
should be evaluated with respect to both their primary preventive abilities
(ie, preventing any event) and their secondary preventive abilities (ie, pre-
venting subsequent events in patients with previous events). This article
indicates that statins have both secondary and primary preventive effects in
patients with transient ischemic attacks or strokes. A statin medication
should be strongly considered in a patient who has a history of TIA or
ischemic stroke.
Endovascular Repair For Aorta-Enteric Fistula: A Bridge Too Far Or a
Bridge To Surgery?
Danneelis MIL, Verhaugen HGN, Teijinki JAW, et al. Eur J Endovasc Surg
2006;32:27-33.
Conclusion: Endovascular treatment of aorta-enteric fistula should be
viewed as a temporizing measure before definitive surgical treatment.
Summary: The authors reviewed their endovascular treatment of aor-
ta-enteric fistula (AEF). Between March 1999 and March 2005, 15 patients
in five university hospitals in Belgium and the Netherlands were treated for
AEF by endovascular techniques. The mean age was 67 years, 80% were
men, and 87% had previous aortic or iliac surgery. Prior surgery varied from
1.7 to 307 months before development of aorta-enteric fistula. At the time
of treatment, 53% of patients were in shock and five (33%) had signs of
systemic infection. In eight cases (53%), the treatment was performed as an
emergency. There were 10 aorta uni-iliac devices placed, three aorta bi-iliac
devices placed, one tube graft placed, and 1 patient was treated with
occluding devices only. All received antibiotics for an extended period of
time postoperatively.
The 30-day mortality was zero. All aortic-enteric fistulas were success-
fully sealed. Mean hospital stay was 20 days (range, 2 to 81 days). There was
one death at 2.7 months of postoperative complications and one death
secondary to lung cancer. Four patients are without late signs of infection.
The mean follow-up in these four patients is 15.7 months (range, 1 to 44
months). Nine patients (60%) had recurrent infection or recurrent aortic-
enteric fistula. This occurred after a mean of 9.5 months (range, 0.6 to 31
months). Seven of these patients were reoperated on successfully and two
died.
Comment: Placement of an aortic stent graft for definitive treatment of
aorta-enteric fistula seems like a silly idea. It violates virtually every known
surgical principle. Nevertheless, it does not seem unreasonable to use an
aortic endograft in patients with aortic-enteric fistula as a temporizing
measure. This can serve to convert an emergency to a more elective situation
and should make a high-risk operation safer.
Overweight, Obesity, And Mortality In A Large Prospective Cohort of
Persons 50 To 71 Years Old
Adams KF, Schatzkin A, Harris TB, et al. N Engl J Med 2006;355:763-78.
Conclusion: There is an increased risk of death during mid life from
excess body weight, including patients who are categorized as overweight
but not obese.
Summary: The authors sought to evaluate the risk of death in both
obese and overweight persons. Obesity is defined as a body mass index
(BMI) of 30.0. Persons are classified overweight when their BMI is
between 25.0 and 29.9. The authors studied the relationship between BMI
and risk of death from any cause in 527,265 men and women in the United
States who are enrolled in the National Institutes of Health/AARP Cohort.
All were 50 to 71 years old at the time of enrollment in 1995 through 1996.
Self-reported weight and height were used to calculate BMI. Relative risk of
death was adjusted for age, level of education, smoking status, race or ethnic
group, alcohol intake, and physical activity. Additional analyses were used to
address potential biases secondary to smoking status and chronic disease
existing at the time of enrollment.
There was a maximum follow-up of 10 years that extended through
2005. During follow-up, 61,317 participants died (42,173 men and 19,144
women). There was an increased risk of death among both men and women
in the highest and lowest categories of BMI. This extended to all racial and
ethnic groups and was present at all ages. Restricting analysis to persons who
had never smoked and who were healthy, the risk of death was increased in
both overweight and obese people in both men and women. Analyzing BMI
during mid life (age 50 years) in subjects who had never smoked, the
association between the risk of death and excess body weight showed a 20%
to 40% increase among overweight persons and a two to three times increase
among obese persons. There was also an increased risk of death among
underweight persons, but this was attenuated compared with overweight
persons.
Comment: One of the realities of Western civilization is that people
tend to gain weight as they age. This article and an accompanying article
(N Engl J Med 2006;355:779-87) suggest that even modest weight gains in
middle age are associated with increased mortality. The mechanism for this
increased mortality in overweight but not obese persons is unknown, but is
postulated to be at least partially related to a chronic inflammatory state
secondary to excess adipose tissue. Whatever the cause, it appears that
middle-aged persons will significantly benefit by reversing the tendency for
the weight gain that accompanies aging.
Aneurysm Syndromes Caused By Mutations In The TGF-Beta Receptor
Loeys BL, Schwarze L, Holm T, et al. N Engl J Med 2006; 355:788-98
Conclusion: Mutations in genes encoding transforming growth fac-
tor- (TGF-) receptors 1 and 2 (TGF BR1 and TGF BR2) results in
aggressive and widespread aneurysmal vascular disease.
Summary: Loeys-Dietz syndrome is an autosomal-dominant aortic
aneurysm syndrome that has been recently described. It is characterized by a
triad of hypertelorism, a bi-fed uvula or cleft palate, and arterial tortuosity in
aneurysms. It is caused by heterozygous mutations in genes or coding for
TGF- receptors 1 and 2. Patients with Loeys-Dietz syndrome are at
significant risk of aortic rupture or dissection at a young age with aortic
diameters that would not generally be predictive of such events. Surgical
intervention is usually successful, distinguishing Loeys-Dietz syndrome
from vascular Ehlers-Danlos syndrome.
In this study, the authors studied 52 affected families with Loeys-Dietz
syndrome. Forty probrands had typical manifestation of Loeys-Dietz syn-
drome. Because there is phenotypic overlap between Loeys-Dietz syndrome
and vascular Ehlers-Danlos syndrome, the authors also screened an addi-
tional 40 patients with vascular Ehlers-Danlos syndrome who did not have
the characteristic type 3 collagen abnormalities or the cranial facial features
of Loeys-Dietz syndrome.
There was a mutation in TGF BR1 or TGF BR2 in all probrands with
typical Loeys-Dietz syndrome (type 1). Mutations were also present in 12
probrands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz
syndrome type 2). Both type 1 and type 2 Loeys-Dietz syndromes were
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